HLB, Stock Price Down 0.6% at This Time... Foreigners Net Buy 156,835 Shares in Last 5 Days

HLB is trading at 116,300 KRW as of 9:30 AM on the 18th, down 0.6% from the previous day. The trading volume is 282,028 shares, which is about 19.9% of the previous day's volume. HLB is known as a manufacturer of lifeboats and fiberglass pipes as well as a construction company.

On September 18, researcher Oh Byung-yong from Hanyang Securities stated, "At the ESMO conference held on 9/19, as many as 20 studies related to Lenvatinib will be presented. Since the company holds all rights to Lenvatinib except for the Chinese license, it is safe to say that all 20 study results are from the company. The combination therapy of Lenvatinib and Camrelizumab for liver cancer shows very outstanding results. Patient recruitment for the global Phase 3 trial of Lenvatinib + Camrelizumab has surpassed 50%. If the global Phase 3 trial again achieves an ORR of over 40%, it opens up the possibility of a huge success." He set the target price for HLB at 144,500 KRW.

Over the past five days, individual investors have net sold 51,002 shares of HLB, while foreigners and institutions have net bought 156,835 shares and net sold 103,221 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.